US News

Creative Biogene Introduces Advanced Premade mRNA Products to Enhance Research Capabilities

Creative Biogene, one of the global leaders in RNA research and biotechnology, has scale-up expertise and unique mRNA, oligonucleotide & plasmid production capabilities for companies focused on therapeutic, vaccine, diagnostic and biopharmaceutical breakthroughs, is excited to announce the launch of its new series of premade messenger ribonucleic acid (mRNA) products tailored for a variety of downstream applications. With a range of manufacturing-grade products from discovery-grade to full GMP-grade, with scale-up and technology transfer expertise and its recent expansion to increase cGMP capacity, Creative Biogene platform provides support from initial research phases to the production of material for use in clinical trials. Creative Biogene is always dedicated to providing researchers with the products and tools they deeply need to advance their research to new frontiers. Messenger RNA (mRNA) plays a crucial role in the central dogma of molecular biology as the intermediary between DNA and protein synthesis. Transcribed from DNA by RNA polymerase through a sophisticated process known as transcription, mRNA serves as the blueprint for protein synthesis. During this pivotal process, RNA polymerase binds to the promoter region of DNA, forming a transcription initiation bubble. This bubble allows nucleotides that are complementary to the DNA template to be added in the 5′-to-3′ direction, ultimately producing the functional mRNA transcript required for protein production. In laboratory settings, this process can be emulated through in vitro transcription (IVT), which combines a DNA template, RNA polymerase, and nucleotide triphosphates (NTPs) within a magnesium-containing buffer. The advantages of IVT-generated mRNA are profound. Notably, this synthetic mRNA does not integrate into the genome, mitigating potential carcinogenic risks. Furthermore, a natural degradation pathway exists for mRNA, ensuring its temporary activity, which is integral for controlled protein expression. Creative Biogene’s premade mRNA products  harness these benefits, enabling researchers to design and sequence-optimize synthetic mRNA molecules. By incorporating modified nucleosides such as 5-methylcytidine (m5C) and pseudouridine (Ψ) during the IVT process, researchers can enhance both the expression levels of proteins and their biological stability while minimizing unwanted immune activation. This innovative approach has triggered an expansive interest in their applications across various biotechnological domains. The implications of synthetic mRNA are enormous. In gene editing, for instance, mRNA can serve as a tool for delivering precise genomic edits smoothly, advancing the fields of gene therapy and regenerative medicine. In immunotherapy, the use of mRNA to boost the body’s immune response against cancer cells or infectious agents is at the forefront of research pursuits, demonstrating exceptional efficacy in recent clinical trials. The versatility of mRNA technology also positions it for significant breakthroughs in cell reprogramming, potentially leading to advancements in personalized medicine and therapeutic interventions. “Our mission is to empower researchers by providing high-quality, affordable premade mRNA products that can facilitate groundbreaking discoveries,” said Marcia Brady, the marketing director of Creative Biogene, “With product and service offerings and expertise that have adapted to customer needs over the decades, we understand the unique challenges researchers face, and we are devoted to assisting our customers overcome these embarrassment with the products and support available.” About Creative Biogene Creative Biogene is always thrilled to offer its portfolio of premade mRNA products. Researchers and institutions can now access these innovative tools to unlock new opportunities in their studies and contribute to the advancement in these fields. Creative Biogene remains committed to taking on challenges others simply will not, continues to expand its cGMP and general mRNA, oligonucleotide & plasmid manufacturing capacity to support therapeutic, vaccine, and diagnostic customers.